Posted by Michael Wonder on 04 Sep 2019
Magenta Therapeutics announces FDA regenerative medicine advanced therapy designation granted to MGTA-456 for the treatment of inherited metabolic disorders
4 September 2019 - Magenta Therapeutics today announced that the U.S. FDA granted regenerative medicine advanced therapy designation for MGTA-456, a one-time cell therapy for the treatment of multiple inherited metabolic disorders.
MGTA-456 is a cell therapy designed to halt the progress of inherited metabolic disorders by providing a high dose of stem cells that regenerate a well-matched new immune system in the patient.
